Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKX019 in Immune-Mediated Diseases
NCT06733935Phase 2Recruiting
- Sponsor
- Nkarta
- Start
- Nov 2024
- Primary completion
- Oct 2028
- Modality
- CAR-T Cells, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of NKX019 in systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM), anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), rheumatoid arthritis (RA), sponsored by Nkarta. Started Nov 2024; status: recruiting.
02
Drugs
NKX019
03
Conditions
systemic sclerosis (SSc)idiopathic inflammatory myopathy (IIM)anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06733935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06733935.